Folks in The Woodlands spend big bucks on the holidays. Visit Houston Texas

If you live in The Woodlands, Sugar Land, or League City, you may be making a holiday shopping list as long as a stocking and checking it more than twice.

These three Houston suburbs rank among the 10 U.S. cities with the fattest holiday budgets, according to a new study from personal finance website WalletHub.

The Woodlands ranks third nationally, at $3,073, while Sugar Land comes in fourth ($3,023) and League City lands at No. 10 ($2,778). Pearland ranks 13th ($2,669) and Missouri City appears at No. 80 ($1,499), while Houston ranks 372nd ($783).

“To help consumers avoid post-holiday regret, WalletHub calculated the maximum holiday budget for each of 570 U.S. cities using five key characteristics of the population, such as income, age, and savings-to-monthly expenses ratio,” the website says.

A suburb of Dallas-Fort Worth wraps up the No. 1 spot on the national list. Flower Mound, according to WalletHub, boasts the most Santa-friendly budget among all the cities: $3,427. Flower Mound ranked second last year ($2,973) and third in 2019 ($2,937).

Seven other DFW cities unwrap rankings in the top 100:

  • Allen, No. 12, $2,688.
  • Frisco, No. 30, $2,133.
  • Plano, No. 33, $2,044.
  • Richardson, No. 43, $1,857.
  • Carrollton, No. 56, $1,698.
  • North Richland Hills, No. 76, $1,544.
  • Irving, No. 89, $1,439.

The two biggest cities in North Texas are on the Scrooge-y side: Fort Worth appears at No. 257 ($920), and Dallas ranks 365th ($787).

In the Austin area, the holiday budgets are more on the lean side, like Santa on a diet:

  • Cedar Park, No. 48, $1,770.
  • Round Rock, No. 134, $1,200.
  • Austin, No. 188, $1,049.

Meanwhile, the San Antonio area’s two entrants on the list feel like they’ve earned lumps of coal:

  • New Braunfels, No. 196, $1,034.
  • San Antonio, No. 371, $783.

“In general, consumers are ready to spend and to have social experiences both within and outside the home. This spurs consumption in multiple categories, including food, décor, apparel, and gifts. This trend toward increased spending is mitigated by lingering COVID health concerns, including reticence to shop in physical stores, gather in groups, and travel,” Barbara Stewart, interim chair of the University of Houston’s Department of Human Development and Consumer Sciences, tells WalletHub.

The National Retail Federation predicts a record-shattering holiday season for retail sales, growing between 8.5 percent and 10.5 percent over 2020 to between $843.4 billion and $859 billion. Meanwhile, professional services firm Deloitte envisions a 7 percent to 9 percent spike in holiday spending this year versus last year. Commercial estate services provider pegs the projected increase at 8.4 percent.

“The outlook for the holiday season looks very bright,” says Jack Kleinhenz, chief economist at the National Retail Federation. “The unusual and beneficial position we find ourselves in is that households have increased spending vigorously throughout most of 2021 and remain with plenty of holiday purchasing power.”

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

Houston energy hub opens new fundraising cohort to fuel startups

Apply Now

EnergyTech Cypher has opened applications for its second Liftoff fundraising program.

Applications close May 20 for the 10-week virtual fundraising sprint. The program is geared toward energy and climatech founders preparing to raise their first institutional round. It will cover fundraising requisites, like pitch materials, term sheet negotiation and round closing, according to a release from EnergyTech Cypher.

The program kicks off June 1 and runs every Monday from 1-3 p.m. CST. It will conclude with an in-person capstone simulation in Houston on August 3, where founders will work to close a mock round.

Jason Ethier, EnergyTech Cypher founder and CEO, will lead the program with Payal Patel, an EnergyTech fellow and entrepreneur in residence.

The program is available through Cephyron, EnergyTech Cypher's new investor relationship management platform, built specifically for energy and climatech founders. Users must have a Cephyron Boost membership to participate in the Liftoff program.

The Cephyron IRM app recently went live and is available to founders at any point in their fundraising process, according to the news release. The platform aggregates investor data, tracks market signals and delivers curated weekly recommendations.

EnergyTech Cypher launched Liftoff last year. The inaugural cohort included 19 startups, including Houston-based AtmoSpark Technologies, The Woodlands-based Resollant and others. Each participant closed at least one fundraising deal, according to EnergyTech Cypher.

EnergyTech Cypher rebranded from EnergyTech Nexus earlier this year. It also launched its CoPilot accelerator in 2025. The inaugural group presented its first showcase during CERAWeek last month.

EnergyTech Cypher's annual Pilotathon Pilot Pitch and Showcase applications also opened this month. Find more information here.

---

This article originally appeared on EnergyCaptialHTX.com.